FIGURE 3:

Relative risk of AKI Stage 2 or 3 within 12 h in the Opal (light gray), Sapphire (medium gray) and combined Opal and Sapphire (dark gray) cohort. Samples were collected within 18 h of enrollment. Risk for each [TIMP-2]•[IGFBP7] range is shown relative to the lowest [TIMP-2]•[IGFBP7] range (≤0.3). Raw risk in lowest stratum = 4.3, 2.7 and 2.9%, respectively, for the Opal, Sapphire and combined cohorts. Error bars indicate the 95% CI. For both cohorts together 700 (46%) of patients had values ≤0.3; 675 (44%) had values between 0.3 and 2 (raw risk of AKI 12.6%); and 154 (10%) had values >2.0 (raw risk of AKI 49%). Cochran–Armitage test for significant trend: P < 0.001 for all three cohorts. Relative risk P < 0.001 for both the second and third stratum relative to the first stratum for all cohorts, except the second stratum of Opal for which relative risk P < 0.01.